Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial
1007 Background: In metastatic breast cancer (MBC), oral capecitabine prescribed at the FDA approved dose of 1250 mg/m 2 twice daily, 14 days on followed by 7 days off, is associated with poor tolerance and high discontinuation rates. Mathematical models suggest a fixed dose, dose dense (7 days on,...
Saved in:
Published in | Journal of clinical oncology Vol. 41; no. 16_suppl; p. 1007 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
01.06.2023
|
Online Access | Get full text |
Cover
Loading…
Abstract | 1007
Background: In metastatic breast cancer (MBC), oral capecitabine prescribed at the FDA approved dose of 1250 mg/m
2
twice daily, 14 days on followed by 7 days off, is associated with poor tolerance and high discontinuation rates. Mathematical models suggest a fixed dose, dose dense (7 days on, 7 days off) schedule may be optimal for capecitabine efficacy. We conducted a randomized trial to compare the efficacy and tolerability of fixed-dose capecitabine, 1500 mg twice daily, 7 days on, 7 days off (FD) to the FDA approved dose and schedule (SD). Methods: Females with MBC and any prior lines of endocrine therapy or chemotherapy were included. HER-2 positive patients were allowed with concurrent trastuzumab. Patients were stratified by line of chemotherapy (first or subsequent), measurable disease, and ER status, and randomized 1:1 to either FD or SD. The primary endpoint was 3-month progression free survival (PFS). Additional endpoints included PFS and overall survival (OS). Capecitabine related toxicities were solicited and graded at each visit. Results: Between October 2015 and April 2021, 153 patients were enrolled (N=80 FD, N=73 SD) . 78% were hormone receptor positive/HER-2 negative, 11% each were HER-2 positive and triple negative. The 3-month PFS was 76% in the FD arm and 76% in the SD arm (HR=1.01; 95% CI, 0.52 to 1.94; p=0.99). Landmark analysis of PFS at 12, 24 and 36 months is reported. Non-proportional hazards were detected, so restricted mean survival time (RMST) was used to report estimates of effect. PFS (restricted mean) at 36 months was 13.9 months in the FD arm versus 14.6 months in the SD arm (hazard ratio for progression or death, 1.31; 95% CI, 0.56 to 1.15; p=0.24). OS (restricted mean) at 36 months was 21.2 months in the FD arm versus 19.6 months in the SD arm (hazard ratio for death, 0.80; 95% CI, 0.55 to 1.81; p=0.27). Toxicity related treatment discontinuation occurred in 21 patients (28.8%) in the SD arm compared to 6 patients (7.5%) in the FD arm (p<0.0006). Grade 2-4 toxicities (Table) occurred more frequently in patients receiving SD capecitabine (49.3%) as compared to FD capecitabine (25.0%) (p=0.0018). Conclusions: Fixed dose capecitabine (1500 mg twice daily) on a 7/7 schedule has less toxicity and similar survival when compared to standard BSA-based dosing on a 14/7 schedule in MBC. Clinical trial information: NCT02595320 . [Table: see text] |
---|---|
AbstractList | 1007
Background: In metastatic breast cancer (MBC), oral capecitabine prescribed at the FDA approved dose of 1250 mg/m
2
twice daily, 14 days on followed by 7 days off, is associated with poor tolerance and high discontinuation rates. Mathematical models suggest a fixed dose, dose dense (7 days on, 7 days off) schedule may be optimal for capecitabine efficacy. We conducted a randomized trial to compare the efficacy and tolerability of fixed-dose capecitabine, 1500 mg twice daily, 7 days on, 7 days off (FD) to the FDA approved dose and schedule (SD). Methods: Females with MBC and any prior lines of endocrine therapy or chemotherapy were included. HER-2 positive patients were allowed with concurrent trastuzumab. Patients were stratified by line of chemotherapy (first or subsequent), measurable disease, and ER status, and randomized 1:1 to either FD or SD. The primary endpoint was 3-month progression free survival (PFS). Additional endpoints included PFS and overall survival (OS). Capecitabine related toxicities were solicited and graded at each visit. Results: Between October 2015 and April 2021, 153 patients were enrolled (N=80 FD, N=73 SD) . 78% were hormone receptor positive/HER-2 negative, 11% each were HER-2 positive and triple negative. The 3-month PFS was 76% in the FD arm and 76% in the SD arm (HR=1.01; 95% CI, 0.52 to 1.94; p=0.99). Landmark analysis of PFS at 12, 24 and 36 months is reported. Non-proportional hazards were detected, so restricted mean survival time (RMST) was used to report estimates of effect. PFS (restricted mean) at 36 months was 13.9 months in the FD arm versus 14.6 months in the SD arm (hazard ratio for progression or death, 1.31; 95% CI, 0.56 to 1.15; p=0.24). OS (restricted mean) at 36 months was 21.2 months in the FD arm versus 19.6 months in the SD arm (hazard ratio for death, 0.80; 95% CI, 0.55 to 1.81; p=0.27). Toxicity related treatment discontinuation occurred in 21 patients (28.8%) in the SD arm compared to 6 patients (7.5%) in the FD arm (p<0.0006). Grade 2-4 toxicities (Table) occurred more frequently in patients receiving SD capecitabine (49.3%) as compared to FD capecitabine (25.0%) (p=0.0018). Conclusions: Fixed dose capecitabine (1500 mg twice daily) on a 7/7 schedule has less toxicity and similar survival when compared to standard BSA-based dosing on a 14/7 schedule in MBC. Clinical trial information: NCT02595320 . [Table: see text] |
Author | Mitchell, Laura Crane, Gregory James Baranda, Joaquina Celebre Monson, Taylor Al-Rajabi, Raed Moh'd Taiseer Khan, Qamar J. Nye, Lauren Elizabeth Raja, Vinay Phadnis, Milind A. Bohnenkamp, Colleen Sharma, Priyanka LaFaver, Stephanie Pluenneke, Robert E. Kasi, Anup Elia, Manana O'Dea, Anne McKittrick, Richard J. Smith, Holly E Fesen, Mark Robert Sheehan, Maureen |
Author_xml | – sequence: 1 givenname: Qamar J. surname: Khan fullname: Khan, Qamar J. organization: University of Kansas Cancer Center, Westwood, KS – sequence: 2 givenname: Colleen surname: Bohnenkamp fullname: Bohnenkamp, Colleen organization: The University of Kansas Health System, Kansas City, KS – sequence: 3 givenname: Taylor surname: Monson fullname: Monson, Taylor organization: The University of Kansas Health System, Kansas City, KS – sequence: 4 givenname: Holly E surname: Smith fullname: Smith, Holly E organization: University of Kansas Medical Center, Department of Biostatistics & Data Science, Kansas City, KS – sequence: 5 givenname: Milind A. surname: Phadnis fullname: Phadnis, Milind A. organization: University of Kansas Medical Center, Department of Biostatistics & Data Science, Kansas City, KS – sequence: 6 givenname: Vinay surname: Raja fullname: Raja, Vinay organization: University of Kansas Cancer Center, Westwood, KS – sequence: 7 givenname: Manana surname: Elia fullname: Elia, Manana organization: University of Kansas Cancer Center, Westwood, KS – sequence: 8 givenname: Anne surname: O'Dea fullname: O'Dea, Anne organization: University of Kansas Cancer Center, Westwood, KS – sequence: 9 givenname: Gregory James surname: Crane fullname: Crane, Gregory James organization: University of Kansas Cancer Center, Westwood, KS – sequence: 10 givenname: Mark Robert surname: Fesen fullname: Fesen, Mark Robert organization: Central Care Cancer Ctr, Great Bend, KS – sequence: 11 givenname: Lauren Elizabeth surname: Nye fullname: Nye, Lauren Elizabeth organization: University of Kansas Cancer Center, Westwood, KS – sequence: 12 givenname: Maureen surname: Sheehan fullname: Sheehan, Maureen organization: University of Kansas Cancer Center, Westwood, KS – sequence: 13 givenname: Robert E. surname: Pluenneke fullname: Pluenneke, Robert E. organization: University of Kansas Cancer Center, Westwood, KS – sequence: 14 givenname: Raed Moh'd Taiseer surname: Al-Rajabi fullname: Al-Rajabi, Raed Moh'd Taiseer organization: University of Kansas Cancer Center, Westwood, KS – sequence: 15 givenname: Joaquina Celebre surname: Baranda fullname: Baranda, Joaquina Celebre organization: University of Kansas Cancer Center, Westwood, KS – sequence: 16 givenname: Anup surname: Kasi fullname: Kasi, Anup organization: University of Kansas Cancer Center, Westwood, KS – sequence: 17 givenname: Richard J. surname: McKittrick fullname: McKittrick, Richard J. organization: University of Kansas Cancer Center, Westwood, KS – sequence: 18 givenname: Laura surname: Mitchell fullname: Mitchell, Laura organization: The University of Kansas Cancer Center, Kansas City, KS – sequence: 19 givenname: Stephanie surname: LaFaver fullname: LaFaver, Stephanie organization: University of Kansas Cancer Center, Westwood, KS – sequence: 20 givenname: Priyanka surname: Sharma fullname: Sharma, Priyanka organization: University of Kansas Cancer Center, Westwood, KS |
BookMark | eNptkNtKAzEQhoNUsFXfIT7AbjPJJtl6J8UjhYJU6F2YzQEj3QPZFdQbX91dqndezfzw_TPwLcisaRtPyBWwHDhjy6f1NueMi7yAHJTp37vukANj-oTMQXKdaS3ljMyZFjyDUuzPyKLv3xiDohRyTr6fsXFtHb-8o0OKeKBtoCF-jNG1vacWO2_jgFVsxtDWHaaJbGk_jEVM_2GxobUfcCSGaGmV_LiORGN9uqa7V0_3mV7q47sLchrw0PvL33lOXu5ud-uHbLO9f1zfbDILTOkMZemUdatQBqewQmlFCAAWQxWUqHywCpTDAoWzEFZoZeW8qiQXArjnK3FOVse7NrV9n3wwXYo1pk8DzEwmzWjSTCZNAebPpJlMih-ioW8d |
CitedBy_id | crossref_primary_10_1038_s41416_024_02700_z crossref_primary_10_1016_j_breast_2024_103677 |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.1200/JCO.2023.41.16_suppl.1007 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1527-7755 |
EndPage | 1007 |
ExternalDocumentID | 10_1200_JCO_2023_41_16_suppl_1007 |
GroupedDBID | --- .55 0R~ 18M 2WC 34G 39C 4.4 53G 5GY 5RE 8F7 AAQQT AARDX AAWTL AAYEP AAYXX ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AIAGR ALMA_UNASSIGNED_HOLDINGS AWKKM BAWUL C45 CITATION CS3 DIK EBS EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 IPNFZ K-O KQ8 L7B LSO MJL N9A O9- OK1 OVD OWW P2P QTD R1G RHI RIG RLZ RUC SJN SV3 TEORI TR2 TWZ UDS VVN WH7 X7M YCJ YFH YQY |
ID | FETCH-LOGICAL-c1067-a58d6cd9f8fd6aba5c3ff11cafbf63befc616da4a3dc1f9ac5bde6b523312e293 |
ISSN | 0732-183X |
IngestDate | Fri Dec 06 06:28:49 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 16_suppl |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c1067-a58d6cd9f8fd6aba5c3ff11cafbf63befc616da4a3dc1f9ac5bde6b523312e293 |
PageCount | 1 |
ParticipantIDs | crossref_primary_10_1200_JCO_2023_41_16_suppl_1007 |
PublicationCentury | 2000 |
PublicationDate | 2023-06-01 |
PublicationDateYYYYMMDD | 2023-06-01 |
PublicationDate_xml | – month: 06 year: 2023 text: 2023-06-01 day: 01 |
PublicationDecade | 2020 |
PublicationTitle | Journal of clinical oncology |
PublicationYear | 2023 |
SSID | ssj0014835 |
Score | 2.4711773 |
Snippet | 1007
Background: In metastatic breast cancer (MBC), oral capecitabine prescribed at the FDA approved dose of 1250 mg/m
2
twice daily, 14 days on followed by 7... |
SourceID | crossref |
SourceType | Aggregation Database |
StartPage | 1007 |
Title | Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial |
Volume | 41 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkCZeEAwQMEBGQnvZks2OcylvqIDKprGBOqlvke3YWoSaTF0msb3wN_k5nBPnBt0ErA9Rk6YnTs_X4y_H50LIGxXuSaTeHjci8GCGUF5iZeQxqRM-ZljxGxOcDz9H0xOxPw_no9HPQdTSRaV8fXVtXslttArHQK-YJfsfmu2EwgF4D_qFLWgYtv-k46-yyMpFfgWk0XXfAOZn8--wm9Vh6BKby1dSIZPsgs2BbHb-g9XT8gKbSkvMM8r1tsKQ9Qojw7RZtgEacw_XX2N3yRvIbZdwWRb6N8f9wanzuH6RC7nc3vc7dwCm3hTf5KLul1e7M_okNTA8TWKYczCsuIWm2DG7SapoXBg86EOtGksXB9wD2zJ3k1JjiXkM1N_V8G1NtWBDSEbpOXY-HZhfDPkYTOXt7so0wV0H7MmRj8PxBfNbYX4vYlia-48pswtkxEcojuuBk6MURaWCpa2ouhz0HXIXSzRiV4f3nw669S2RuNav7Y2vk9fNuHZvHNWAOQ0o0OwBud-ol75zQHxIRqbYIOuHTXTGBtk6dnXQL3forE_rO9-hW_S4r5B--Yj86IFLaxTR0tIauBQRSYeIpC1waVXSFrjXnJYXtAcudcClDrhvcTgUYLsbu8s9JicfP8wmU6_pBOJpLHHoyTDJIp2NbWKzSCoZ6sBaxrS0ykaBMlZHLMqkkEGmmR1LHarMRCrkQcC4AUb7hKwVZWGeEsqMYDIywgp4ZfBZEvM9EMc0MF-h2TPC2185PXMFX9K_avn5bb60Se71f4YXZK1aXpiXwHAr9aoGyy89nqgq |
link.rule.ids | 314,780,784,27924,27925 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Randomized+trial+of+fixed+dose+capecitabine+compared+to+standard+dose+capecitabine+in+metastatic+breast+cancer%3A+The+X-7%2F7+trial&rft.jtitle=Journal+of+clinical+oncology&rft.au=Khan%2C+Qamar+J.&rft.au=Bohnenkamp%2C+Colleen&rft.au=Monson%2C+Taylor&rft.au=Smith%2C+Holly+E&rft.date=2023-06-01&rft.issn=0732-183X&rft.eissn=1527-7755&rft.volume=41&rft.issue=16_suppl&rft.spage=1007&rft.epage=1007&rft_id=info:doi/10.1200%2FJCO.2023.41.16_suppl.1007&rft.externalDBID=n%2Fa&rft.externalDocID=10_1200_JCO_2023_41_16_suppl_1007 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon |